CalciMedica (NASDAQ:CALC) Stock Price Up 1% – Here’s What Happened

CalciMedica, Inc. (NASDAQ:CALC)’s stock price was up 1% on Monday . The stock traded as high as $4.15 and last traded at $4.12. Approximately 4,224 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 31,052 shares. The stock had previously closed at $4.08.

Wall Street Analysts Forecast Growth

CALC has been the subject of several analyst reports. Oppenheimer boosted their price target on shares of CalciMedica from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, July 10th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of CalciMedica in a research note on Tuesday, August 13th. Finally, Singular Research upgraded CalciMedica to a “moderate buy” rating in a research note on Friday, June 28th.

CalciMedica Price Performance

The company has a market capitalization of $44.29 million, a PE ratio of -1.92 and a beta of 1.27. The company’s 50 day simple moving average is $4.30 and its 200 day simple moving average is $4.66.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.03. On average, equities analysts forecast that CalciMedica, Inc. will post -2.21 EPS for the current year.

Insider Transactions at CalciMedica

In other news, Director Robert N. Wilson purchased 54,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The shares were purchased at an average price of $3.72 per share, for a total transaction of $200,880.00. Following the purchase, the director now directly owns 364,196 shares of the company’s stock, valued at $1,354,809.12. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders have bought 65,000 shares of company stock worth $243,120. Corporate insiders own 53.30% of the company’s stock.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.